Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fractional Booster Doses of COVID-19 Vaccines
NCT05343871Phase 4Completed
- Sponsor
- Sabin Vaccine Institute
- Start
- Jul 2022
- Primary completion
- Jul 2023
- Modality
- Viral Vector Vaccines, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 2
01
Overview
A Phase 4 trial of tozinameran, ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19), sponsored by Sabin Vaccine Institute. Started Jul 2022; status: completed.
02
Drugs
tozinameranChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05343871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05343871.